Notably, MCL1, whose overexpression directly mediates VEN resistance, is also a therapeutic target of HHT in AML; thus, HHT has the potential to prevent and overcome VEN resistance when used in combination with VEN [24, 25]. Here, ACVRL1 is linked to acute myeloid leukemia.